Publication | Open Access
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results
38
Citations
34
References
2023
Year
Proprietary or commercial disclosure may be found after the references.
| Year | Citations | |
|---|---|---|
Page 1
Page 1